Trudy Lieberman praises an NPR followup on the FDA's approval of sofosbuvir to treat hepatitis C. Unlike most initial reporting, the followup focused on the pill's $1,000 cost: "What makes the story stand out are the interviews with a researcher at the University of Liverpool and a doctor at Boston’s Beth Israel Deaconess Medical Center, each of whom question the drug’s stratospheric cost. Their remarks provide a much-needed perspective on pharmaceutical pricing."
.png)
